SCHEMBL29873567

SCHEMBL29873567

COc1ccc(CN(Cc2ccc(OC)cc2)c2nn(Cc3ccc(OC)cc3)c3ncc(Nc4ccc([N+](=O)[O-])cc4)cc23)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ ALDH1A1 P00352 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ HPGD P15428 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ PIK3CA P42336 1/20 0.39
▸ PIK3CB P42338 1/20 0.39
▸ PIK3CG P48736 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ CCNE2 O96020 1/20 0.38
▸ CCNE1 P24864 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29873266 0.87 MAPT (0.45) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL29872467 0.87 ALDH1A1 (0.46) MAPTSMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL29872415 0.76 PDE1B (0.40) MAPTSMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL23069180 0.72 MAPT (0.50) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL29872970 0.72 MAPT (0.49) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL1593005 0.72 MAPT (0.51) MAPTSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL1593522 0.69 CNR2 (0.50) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL12821734 0.69 PDE1B (0.49) MAPTSMN1; SMN2ALDH1A1LMNAHPGD
SCHEMBL29873129 0.68 MAPT (0.46) MAPTSMN1; SMN2NPC1RAB9ALMNA
SCHEMBL1195949 0.68 MAPT (0.68) MAPTSMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220306640-A1 HYDANTOIN DERIVATIVE ONO PHARMACEUTICAL CO., LTD. (JP) 2022-09-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306640-A1 HYDANTOIN DERIVATIVE DDR1, DDR2, DDRGK1 MAPT 3943/4885SMN1; SMN2 1226/4885NPC1 3102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback